| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash used in investing activities | -98,147 | -39,592 |
| Proceeds from issuance of common stock upon exercise of stock options and purchases under employee stock purchase plan | 20,506 | 14,847 |
| Tax withholding payments related to net settlement of restricted stock units | 479 | 479 |
| Net cash provided by financing activities | 20,027 | 14,368 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 16,526 | 71,359 |
| Cash and cash equivalents at beginning of period | 97,474 | - |
| Cash and cash equivalents at end of period | 114,000 | - |
Protagonist Therapeutics, Inc (PTGX)
Protagonist Therapeutics, Inc (PTGX)